Press releases
- Enanta Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- Enanta Pharmaceuticals Announces the Appointment of Matthew P. Kowalsky as Chief Legal Officer
- Enanta Pharmaceuticals to Host Conference Call on May 6 at 4:30 p.m. ET to Discuss its Financial Results for its Fiscal Second Quarter Ended March 31, 2024
- Enanta Pharmaceuticals Announces Data Presentation at ESCMID Global 2024
- Enanta Pharmaceuticals to Participate at Leerink Partners Global Biopharma Conference
- Enanta Pharmaceuticals Reports Financial Results for its Fiscal First Quarter Ended December 31, 2023 with Webcast and Conference Call Today at 4:30 p.m. ET
- Enanta Pharmaceuticals to Participate at the Oppenheimer 34th Annual Healthcare Life Sciences Conference
More ▼
Key statistics
On Tuesday, Enanta Pharmaceuticals Inc (9EP:DUS) closed at 12.90, 13.16% above the post-IPO low of 11.40 set on Apr 29, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 12.20 |
---|---|
High | 12.90 |
Low | 12.20 |
Bid | 12.70 |
Offer | 13.00 |
Previous close | 12.10 |
Average volume | 0.00 |
---|---|
Shares outstanding | 21.16m |
Free float | 19.87m |
P/E (TTM) | -- |
Market cap | 290.68m USD |
EPS (TTM) | -6.56 USD |
Data delayed at least 15 minutes, as of Apr 30 2024 18:30 BST.
More ▼